https://www.businesswire.com/news/h...nsor-Studies-Teams-Up-with-Leading-Clinicians
Summary
DALLAS--(BUSINESS WIRE)--EnLiSense CCM, a pioneer in non-invasive, real-time inflammatory biomarker monitoring, announces the initiation of multiple groundbreaking clinical studies in collaboration with top-tier medical institutions to further the management of Inflammatory Bowel Disease (IBD). Building on the momentum from the previous venture funding by the Crohn's and Colitis Foundation, EnLiSense CCM is partnered with premier medical institutions like the University of Chicago, Mount Sinai, University of Glasgow, and University of Texas Dallas to develop a decision-support tool for physicians and patients
Summary
DALLAS--(BUSINESS WIRE)--EnLiSense CCM, a pioneer in non-invasive, real-time inflammatory biomarker monitoring, announces the initiation of multiple groundbreaking clinical studies in collaboration with top-tier medical institutions to further the management of Inflammatory Bowel Disease (IBD). Building on the momentum from the previous venture funding by the Crohn's and Colitis Foundation, EnLiSense CCM is partnered with premier medical institutions like the University of Chicago, Mount Sinai, University of Glasgow, and University of Texas Dallas to develop a decision-support tool for physicians and patients